Cancer Research Technology
Log in Register
Menu

T47D/TR-1 Cell Line

Invented by Dr Anne Lykkesfeldt from Danish Cancer Society
Invented at Danish Cancer Society

Info

Catalogue Number 152108
Antigen/Gene or Protein Targets Oestrogen receptor
Parental Line T47D/S2
Host Human
Tissue Breast
Disease Keywords Breast carcinoma, tamoxifen resistant
Model Tumour line
Relevance The T47D/TR-1 Cell line is a breast cancer cell line resistant to tamoxifen. Antiestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial. This cell line allows the study of the mechanisms involved in tamoxifen resistant breast cancer cell growth.
Production Details The T47D/TR-1 cell line has been established by long term treatment of T47D/S2 cells with 1 µM tamoxifen. Clonal selection was performed in medium without tamoxifen. After growth in presence of 1 µM tamoxifen for 10 months, the growth rate was similar to the parental cells.
Research Area Cancer, Drug Discovery & Development
Recommended Growing Conditions Phenol red free RPMI 1640 + 2% FCS + glutamax + 8µg Insulin/ml + 1 uM tamoxifen
Notes T47D/TR-1 cells are ER alpha positive and express progesterone receptor, although at reduced level compared to parental T7D/S2 cells. T47D/TR-1 are growth inhibited by fulvestrant.

Passage 164 (AL3569, AL3570)
Cellosaurus ID CVCL_1D36

References

There are 8 reference entries for this reagent.

View All References

References: 8 entries

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

Europe PMC ID: 25885472

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Europe PMC ID: 25706943

Thrane et al. 2014. Oncogene. :. PMID: 25362855.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Europe PMC ID: 25362855

Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.

Europe PMC ID: 24513268


Add a reference

References: 8 entries

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Thrane et al. 2014. Oncogene. :. PMID: 25362855.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.


Add a reference